Zai Lab (MEX:ZLAB) Tax Provision : MXN0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Zai Lab Tax Provision?

Zai Lab's tax provision for the three months ended in Jun. 2024 was MXN0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was MXN0 Mil.

Zai Lab Tax Provision Historical Data

The historical data trend for Zai Lab's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Tax Provision Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

Zai Lab Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Zai Lab Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

Zai Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (MEX:ZLAB) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

ZLAB:USA 09688:Hong Kong 1ZLB:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.